Amgen

AmgenAmgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

www.amgen.com

Amgen RSS Channel

Display # 
Title Published Date
Amgen and UCB announce positive top-line tesults from phase 3 study evaluating romosozumab In men with osteoporosis 21 March 2016
Amgen reacquires all product rights to Prolia® (denosumab), XGEVA® (denosumab) and Vectibix® (panitumumab) from GSK in 48 countries 15 December 2015
FDA approves IMLYGICTM (talimogene laherparepvec) as first oncolytic viral therapy in the US 28 October 2015
Amgen to acquire privately-held Dezima Pharma 16 September 2015
Amgen and Xencor announce strategic collaboration in cancer immunotherapy and inflammation 16 September 2015
European Commission approves Amgen's new cholesterol-lowering medication Repatha™ (evolocumab) 23 July 2015
Amgen announces collaboration with Roche on cancer immunotherapy study with investigational medicines talimogene laherparepvec and atezolizumab 02 June 2015
Amgen receives FDA Breakthrough Therapy Designation for investigational BiTE® antibody blinatumomab in acute lymphoblastic leukemia 01 July 2014
Amgen and Merck announce collaboration To evaluate investigational combination treatment for advanced melanoma 05 February 2014
Amgen Foundation commits $2.5 million in new grants to engage 50,000 students each year in the thrill of scientific inquiry 07 November 2013
Amgen's third quarter 2013 revenues increased 10 percent 24 October 2013
Amgen acquires Filgrastim franchise rights from Roche In 100 markets 22 October 2013
Amgen successfully completes Onyx Pharmaceuticals tender offer 02 October 2013
Amgen and ShanghaiTech University announce plans for Amgen China R&D center 25 September 2013
Amgen to acquire Onyx Pharmaceuticals for $125 per share in cash 26 August 2013
FDA approves Amgen's XGEVA® (denosumab) for the treatment of giant cell tumor of bone 16 June 2013
Amgen and Astellas announce Japan Alliance 29 May 2013
Amgen and Zhejiang Beta Pharma announce planned joint venture in China 10 May 2013
Amgen announces top-line results of phase 3 talimogene laherparepvec trial in melanoma 20 March 2013
Amgen's full year 2012 revenues increased 11 percent to $17.3 billion 23 January 2013

Most Popular Now

AstraZeneca and Eli Lilly and Compa…

AstraZeneca and Eli Lilly and Company today announced that AMARANTH, a Phase II/III study of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in...

Read more

NIH launches large clinical trials …

Enrollment has begun in the first of two multinational clinical trials of an intravenously delivered investigational antibody for preventing HIV infection. Known as the A...

Read more

Pfizer announces termination of pro…

Pfizer Inc. (NYSE: PFE) announced that the merger agreement between Pfizer and Allergan plc (NYSE: AGN) has been terminated by mutual agreement of the companies. The deci...

Read more

New analysis shows only minority of…

Boehringer Ingelheim has announced a new publication showing that levels of white blood cells called eosinophils can help identify patients with COPD who may and may not ...

Read more

Researchers open the way to new tre…

In a recent paper published in Nature Communications, a group of Case Western University School of Medicine researchers presented their discovery of the full-length struc...

Read more

Implantable device targets pancreat…

Pancreatic cancer is the third leading cause of cancer deaths in the United States, in part because it is very difficult for chemotherapy drugs to reach the pancreas, whi...

Read more

Physicians' knowledge about FDA app…

Since 2012, the FDA can designate a drug as a "breakthrough therapy" if preliminary clinical evidence - such as an improvement in a pharmacodynamic biomarker - suggests a...

Read more

FDA grants priority review for Roch…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) and granted P...

Read more

Global spending on health is expect…

Global inequities in health spending are expected to persist and intensify over the next 25 years, according to a new study that estimates total health financing in count...

Read more

Americans live longer but with disa…

Americans are living longer but in poorer health, according to a new study. The USC-led study examined life expectancy trends and disability rates in a 40-year period, fr...

Read more

Nanoparticles show promise for trea…

Nanoparticles designed to block a cell-surface molecule that plays a key role in inflammation could be a safe treatment for inflammatory bowel disease (IBD), according to...

Read more

Johnson & Johnson announces lau…

Johnson & Johnson today announced the official launch of its global public health strategy at the opening of its companies' on-the-ground global public health operations ...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]